Keywords:
Genital / Reproductive system male, MR, Diagnostic procedure, Neoplasia
Authors:
C. Gianneramo1, L. Panebianco1, A. pace1, A. Izzo2, M. Martino3, F. Formiconi1, R. Manetta1, C. Masciocchi1; 1L'Aquila/IT, 2vallata/IT, 3Rome, ITALY/IT
DOI:
10.26044/ecr2019/C-1133
Aims and objectives
Prostate cancer accounts for about 20% of all cancers diagnosed among men aged 50 and older.
At the base of this phenomenon,
there is the greatest probability of diagnosing this disease,
which is present in a latent form in 15-30% of the subjects over 50 years and in about 70% of the octogenarians.
In recent years,
enormous progress has been made in prostate imaging thanks to multiparametric MRI (mpMRI),
which provides a high spatial resolution(<1mm) morphological images and functional images,
with information on cellularity and vascularization of possible lesions.
At the same time,
it was introduced the possibility to perform targeted biopsies on the lesions identified with the resonance by using RM-US fusion images.
In this context,
it is now essential to identify in a more specific way,
the lesions that can be clinically significant (with a Gleason score (GS) equal to or greater than 7).
Psa density,
initially calculated with ultrasound,
has always been a parameter in the detection of prostate cancer; some studies have recently correlated this parameter with the PI-RADS score in the identification of clinically significant prostate tumors [1-8].
The aim of this study is to demonstrate the usefulness of PSA density (PSAD) in association with PI-RADS score-v2 in identifying clinically significant tumors in patients undergoing fusion biopsy.